Ob/Gyn Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma
Cancer, 03/25/09

Fader AN et al. - In a trial to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) pts, it was found that these pts have significant risk for extrapelvic recurrence and poor survival. Recurrence and survival outcomes are improved in well-staged pts treated with platinum/taxane-based chemotherapy.

Methods

A retrospective study of stage I UPSC pts diagnosed from 1993 to 2006 was performed.
Pts underwent comprehensive surgical staging; postoperative treatment included observation (OBS); radiotherapy alone (RT); or platinum/taxane-based chemotherapy (CT) ± RT.

Results

142 pts were identified with a median follow-up of 37 mos.
33 pts were observed, 20 received RT alone, and 89 received CT ± RT.
25 recurrences (17.6%) were diagnosed, and 60% were extrapelvic.
Chemotherapy-treated pts experienced significantly fewer recurrences than those treated without chemotherapy.
CT ± RT pts had a lower risk of recurrence (11.2%) vs pts who received RT alone (25%) or OBS (30.3%).
This effect was most pronounced in stage IB/IC.
CT- and CT + RT-treated pts experienced similar recurrence.
After multivariate analysis, treatment with chemotherapy was associated with a decreased risk of recurrence.
Majority of recurrences (88%) were not salvageable.
Progression-free survival (PFS) and cause-specific survival (CSS) for chemotherapy-treated pts were more favorable than for those who did not receive chemotherapy.
5-yr PFS and CSS rates were 81.5% and 87.6% in CT ± RT, 64.1% and 59.5% in RT alone, and 64.7% and 70.2% for OBS.